

Prescribing Clinical Network

Policy Statement	Apremilast (Otezla) for the treating active Psoriatic Arthritis (NICE TA433)
Policy No:	PCN 265-2017
Date of Issue	May 2017
Review Date:	May 2020 (Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)
Recommendations: The PCN recommends Apremilast as a treatment option for treating active psoriatic arthritis in line with NICE TA433 (22 nd February 2017). Apremilast is a payment by results excluded drug which will be considered RED on the traffic light system. The current psoriatic arthritis treatment pathway will be available on the prescribing advisory database.	
Key considerations: <ul style="list-style-type: none">NICE TA433 – Apremilast for the treating active Psoriatic Arthritis https://www.nice.org.uk/guidance/ta433/resources/apremilast-for-treating-active-psoriatic-arthritis-pdf-82604722478533	
Date taken to Prescribing Clinical Network	3rd May 2017
Agreed by PCN members	12 th May 2017